Privately owned lipid metabolite research and analysis company names Thomas Anderson as CEO and Steven Watkins as CSO
Lipomics Technologies, a privately owned company that specialises in lipid metabolite research and analysis services, has named Thomas Anderson as CEO of the company and Steven Watkins as CSO (chief scientific officer).
Prior to joining Lipomics in 2002 as vice president of business development, Anderson was a consultant to a number of companies with interests in biotechnology.
He was also founder and president of Berkeley Antibody (Babco), which he sold to Covance Research Products in 1988.
Watkins, a founder of Lipomics and president since inception, has accepted the additional position of CSO, which will allow him to further develop the company's proprietary lipid metabolite research. "Since joining Lipomics, Tom has made valuable contributions to build the company's position as the leading firm offering lipid metabolomic services to the pharmaceutical industry's drug discovery process," said Charles Soderquist, chairman of Lipomics.
"We look forward to a vibrant future for the company through his continued vision and leadership as our new CEO.
"I am also pleased to announce Steve's appointment as the company's chief scientific officer.
Lipomics recognises his extensive talent and knowledge of lipid metabolism as a research and discovery tool." "My first year at Lipomics has convinced me that metabolomics in general and our company's technology in particular, is going to have significant impact on both drug discovery and on personalised and predictive medicine," said Anderson.
"In my new position, I will be able to work side by side with Steve to build this company, and to see the results of our efforts in improved human health through more effective drug discovery processes."
